Pineapple Energy Reports Fourth Quarter 2022 Financial Results

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Revenue +192% from Q3 2022 Gross profit +256% from Q3 2022 GAAP Net Loss ($539k), pro forma adjusted EBITDA ($170k) Increased pending installations to $47 million as of year-end $8 million of cash, restricted cash, and investments Completed acquisition of SUNation, leading New York installer, tripling revenue run rate MINNETONKA, Minn., March 30, 2023 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (NASDAQ:PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced select financial results for the fourth quarter ended December 31, 2022. Results reflect a partial quarter of contribution from SUNation, the acquisition of which closed on November 9, 2022. Pineapple CEO Kyle Udseth commented, “What a difference a year makes. We entered 2022 as a small private company with big...

Sachem Capital Reports Record 2022 Annual Revenue of $52.3 Million and Net Income Attributable to Common Shareholders of $17.2 Million or $0.46 per Share

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Conference Call and Webcast to be held at 8:00 AM ET on Friday, March 31, 2023 BRANFORD, Conn., March 30, 2023 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced its financial results for the year ended December 31, 2022. The company will host a conference call on Friday, March 31, 2023 at 8:00 a.m. Eastern Time to discuss in greater detail its financial and operating results for 2022. John Villano, CPA, the company’s Chief Executive Officer, stated: “2022 was another record year for our company with revenue of $52.3 million and net income attributable to common shareholders of $17.2 million. Earnings per share was $0.46 per share compared to $0.44 for the prior year. Further we achieved approximately $20.2 million of non-GAAP adjusted earnings or $0.53 per share in earnings, reflecting the strength of our...

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to be completed in 2023 Topline results from the Phase 3 clinical program of DFD-29 to treat papulopustular rosacea expected in the first half of 2023; NDA submission expected in the second half of 2023 MIAMI, March 30, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising...

Clever Leaves Reports Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

– Fourth Quarter and Full Year 2022 Cannabinoid Revenue Increased 71% and 90%, Respectively; Total Annual Revenue Growth was 16% Year-over-Year – – Steady Cost Reductions and Portugal Wind-Down Expected to Drive Production, Cost, and CapEx Efficiencies – – Announces Financial Outlook and Key Focus Markets for 2023 – TOCANCIPÁ, Colombia, March 30, 2023 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2022. All financial information is provided in US dollars unless otherwise indicated. “2022 was a transformational year for Clever Leaves as we executed...

Silver Spike Investment Corp. Reports Fiscal Year End 2022 Financial Results

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — Silver Spike Investment Corp. (“Silver Spike” or the “Company”), a specialty finance company that was formed to invest across the cannabis ecosystem through investments primarily in the form of direct loans to privately held cannabis companies, today announced its financial results for the fiscal year ended December 31, 2022. Quarter Ended 12/31/22 Highlights Total investment income of $2.0 million Net investment income of $1.4 million, or $0.23 per share Investment portfolio of $50.3 million at fair value Net asset value (“NAV”) per share increased to $13.91 on December 31, 2022 from $13.73 on September 30, 2022 Scott Gordon, Chairman and Chief Executive Officer of Silver Spike, commented, “We continue to build a robust portfolio of loans to the cannabis industry’s top operators,...

Rumble Reports Record Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

~ Q4 Revenue Increased 579% to $20.0 Million Compared to Q4 2021; Full Year 2022 Revenue Increased 316% ~ ~ Achieved Q4 2022 Company Record Key Performance Indicators ~ ~ Average Global Monthly Active Users Increased to 80 Million, Up 142% Compared to Q4 2021 ~ ~ Completed Significant Milestone with Beta Launch of Pre-Roll Video Ads on Advertising Center ~ LONGBOAT KEY, Fla., March 30, 2023 (GLOBE NEWSWIRE) — Rumble Inc. (“Rumble”) (NASDAQ: RUM), the popular video-sharing platform, announced today financial results for the fiscal quarter and full year ended December 31, 2022. Q4 and Full Year 2022 Key Highlights Average global Monthly Active Users (“MAUs”) increased 142% to 80 million, a company record, compared to 33 million in the fourth quarter of 2021. Of the 80 million, 65 million were based in the U.S. and Canada, compared...

GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line

Written by Customer Service on March 30, 2023. Posted in Mergers And Acquisitions.

GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line Image: GreenLight Biosciences BOSTON, March 30, 2023 (GLOBE NEWSWIRE) — GreenLight Biosciences (Nasdaq: GRNA) (“GreenLight” or the “Company”), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today, confirmed that it has received a non-binding indication of interest from Fall Line Endurance Fund, L.P. (“Fall Line”) to acquire all of the outstanding capital stock of the Company for $0.60 per share in cash (the “Proposed Transaction”). The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction...

ATA Creativity Global Reports 2022 Fourth Quarter and Year-end Financial Results

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Conference Call on Thursday, March 30, 2023, at 9 p.m. ET with Accompanying Investor Presentation BEIJING, March 30, 2023 (GLOBE NEWSWIRE) — ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students’ creativity, today announced preliminary unaudited financial results for the quarter and year ended December 31, 2022 (“Fourth Quarter 2022” and “Fiscal Year 2022”, respectively). Fourth Quarter 2022 and Fiscal Year 2022 Highlights Fourth Quarter 2022 net revenues increased 8.2% to RMB78.5 million (US$11.4 million), from RMB72.6 million in the prior-year period. Fourth Quarter 2022 net income attributable to ACG was RMB2.0 million (US$0.3 million), compared to net loss of RMB2.5 million in the prior-year...

Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining a clear path forward for the program Entered into co-development agreement with Formosa Pharmaceuticals Company to host conference call and webcast today, March 30th, at 4:30 pm ET NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced its financial and operating results for the fourth...

Reliance Global Group Achieves 73% Increase in Revenue to $16.8 Million for 2022

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Reports Continued Growth of RELI Exchange Platform Company to Host Conference Call Today at 4:30 PM Eastern Time LAKEWOOD, N.J., March 30, 2023 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI; RELIW) (“Reliance”, “we” or the “Company”), today provided a business update and reported financial results for the year-ended December 31, 2022. Ezra Beyman, CEO of Reliance, commented, “We are extremely pleased to report a 73% increase in revenue in 2022 as compared to 2021. This achievement was due to the growth and overall solid performance from our ten operating subsidiaries. We are also very proud of our most recent business formation, RELI Exchange, built on the foundations of Barra & Associates, an agency we acquired in April 2022. RELI Exchange is a business-to-business (B2B) InsurTech platform and agency partner...

Day: March 30, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice